Chandra Bhagat Pharma Limited has convened its 23rd Annual General Meeting (AGM) for Tuesday, September 1, 2026, at 4:00 P.M. IST at its registered office in Mumbai. The meeting aims to secure shareholder approval for a significant capital raising exercise through the preferential allotment of Convertible Warrants, alongside an increase in authorized share capital and routine board appointments. The proposed warrant issue is designed to raise up to ₹29.04 crore to meet working capital requirements and general corporate purposes, signaling management's intent to fund future expansion in the pharmaceutical sector.

The special resolution seeks approval to issue up to 66,00,000 Convertible Warrants on a private placement basis to promoters and non-promoters. Each warrant carries a face value of ₹10 and will be issued at a price of ₹44 per warrant, including a premium of ₹34. The warrants are exercisable into equity shares within 18 months of allotment. If not exercised within this period, the warrants will lapse, and the amount paid will be forfeited by the company. The pricing is based on the volume-weighted average price (VWAP) as per Regulation 164 of the SEBI ICDR Regulations, with a valuation certificate obtained from ValuGenius Advisors LLP.

In addition to the warrant issue, the ordinary resolution proposes increasing the company’s authorized share capital from ₹8.50 crore (85,00,000 equity shares of ₹10 each) to ₹15.00 crore (1,50,00,000 equity shares of ₹10 each). This increase creates headroom for the eventual conversion of warrants into equity shares and supports future fundraising needs. The explanatory statement notes that raising funds via convertible warrants requires sufficient authorized capital, necessitating this amendment to Clause V of the Memorandum of Association.

Financial Performance and Outlook

The AGM notice accompanies the annual report for the financial year ended March 31, 2026 (FY26). During FY26, Chandra Bhagat Pharma reported a profit after tax (PAT) of ₹304.61 lakh, a substantial increase from ₹85.78 lakh in FY25. Revenue from operations rose to ₹11,627.17 lakh in FY26, compared to ₹8,880.54 lakh in the previous year. The company attributed this growth to higher turnover in pharmaceutical formulations and API products, particularly in export markets where foreign exchange earnings reached ₹8,024.23 lakh.

Management highlighted robust growth prospects, citing plans to expand into vaccine formulations, including Hepatitis A and Inactivated Polio Vaccine, and to set up dedicated manufacturing facilities. The funds raised from the warrant issue are earmarked for working capital and general corporate purposes over a two-year timeline. No dividend was recommended for FY26, as profits were retained to support these expansion initiatives.

Board Appointments and Governance

The AGM agenda includes the re-appointment of Mr. Pranav Hemant Bhagat (DIN: 00156362), Whole Time Director, who retires by rotation. He has offered himself for re-appointment and is eligible under the Companies Act, 2013. The board also comprises Hemant Chandravadan Bhagat (Managing Director), Prachi Pranav Bhagat (Director and CFO), and independent directors Ravindra Gajanan Awati and Abha Praveen Doshi.

The statutory auditors, M/s. A Y & Company, Chartered Accountants, have submitted their report without qualifications. The secretarial audit report by M/s. Amit Dharmani & Associates confirms compliance with applicable statutory provisions. Shareholders holding shares in physical form are advised to update their details with MUFG Intime India Private Ltd., the registrar and share transfer agent, while demat holders must coordinate with their depository participants.

Chandra Bhagat Pharma has scheduled a meeting of its Board of Directors for August 5, 2026, to consider a proposal for raising capital through the preferential allotment of equity shares, convertible warrants, or other instruments. The Board will also deliberate on increasing the company's authorized share capital and determining the date, time, and place for an Extraordinary General Meeting (EOGM) to obtain shareholder approval for these measures. This move signals the company's intent to strengthen its balance sheet or fund specific corporate initiatives, subject to regulatory compliances and shareholder consent.

The filing, submitted under Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, outlines the key agenda items for the upcoming session. In addition to the fund-raising proposal and capital increase, the Board will address any other business incidental and ancillary to the primary agenda, with the permission of the chair. The final terms of the preferential issue, including pricing and allocation, will be determined during this meeting before being presented to shareholders.

In accordance with the Code of Conduct for prevention of insider trading, framed under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the company's securities is closed. This restriction applies to all connected persons, officers, designated employees, directors, and their immediate relatives from July 30, 2026, until the end of 48 hours from the conclusion of the Board Meeting. This measure ensures fair disclosure and prevents insider trading ahead of material announcements.

The preferential allotment route allows the company to raise funds from specific investors without a public issue, often used for strategic partnerships or quick capital infusion. The inclusion of convertible warrants as a potential instrument suggests flexibility in structuring the deal to meet investor requirements while potentially deferring immediate equity dilution. The subsequent EOGM is a mandatory step to ensure that existing shareholders have the opportunity to approve the issuance of new securities, which could impact their ownership percentage.

What the Numbers Show

While specific financial figures regarding the amount to be raised or the valuation of the shares are not disclosed in this preliminary intimation, the decision to increase authorized share capital indicates a strategic preparation for future growth or restructuring. The dual focus on capital raising and authorized capital expansion suggests that Chandra Bhagat Pharma is positioning itself for significant operational changes or investments that require both immediate funding and long-term equity capacity. Investors will need to monitor the EOGM notice for detailed terms, including the issue price and the identity of potential allottees, which will provide clearer insights into the company's financial strategy.